Altimmune (ALT) Operating Margin (2010 - 2025)
Altimmune (ALT) reported Operating Margin of 111126.92% for Q4 2025, up 38619308.0% year-over-year from N/an in Q4 2024, and up 73.36% quarter-over-quarter from 417180.0% in Q3 2025.
Altimmune (ALT) Operating Margin (2010 - 2025) Analysis & Trends
Altimmune (ALT) has 16 years of Operating Margin data on file, last reported at 111126.92% in Q4 2025.
- Operating Margin for Q4 2025 came in at 111126.92%, up 38619308.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 230460.98% (up 28539902.0% YoY), and the FY2025 annual result was 230460.98%, up 28539902.0% from the prior year.
- Operating Margin advanced to 111126.92% in Q4 2025 per ALT's latest filing, from 417180.0% in the prior quarter.
- Over five years, Operating Margin peaked at 731.92% in Q4 2021 and troughed at 1237600.0% in Q3 2022.
- A 5-year average of 283564.09% and a median of 183032.21% in 2025 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2022 and 2023: Operating Margin sank 121658481 bps in 2022, then soared 123137348 bps in 2023.
- A 5-year view of Operating Margin shows it stood at 731.92% in 2021, then slumped by 12036 bps to 88823.08% in 2022, then decreased by 2 bps to 90872.97% in 2023, then tumbled by 447 bps to 497320.0% in 2024, then jumped by 78 bps to 111126.92% in 2025.
- Business Quant data shows ALT's Operating Margin at 111126.92% in Q4 2025, 417180.0% in Q3 2025, and 458440.0% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Altimmune | 336.67 Mn | 336.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -111,126.92% |
| Sep 30, 2025 | -417,180.00% |
| Jun 30, 2025 | -458,440.00% |
| Mar 31, 2025 | -436,300.00% |
| Dec 31, 2024 | -497,320.00% |
| Sep 30, 2024 | -495,340.00% |
| Jun 30, 2024 | -534,900.00% |
| Mar 31, 2024 | -535,880.00% |
| Dec 31, 2023 | -90,872.97% |
| Sep 30, 2023 | -6,226.52% |
| Jun 30, 2023 | -300,116.67% |
| Mar 31, 2023 | -103,614.29% |
| Dec 31, 2022 | -88,823.08% |
| Sep 30, 2022 | -1,237,600.00% |
| Jun 30, 2022 | -254,937.50% |
| Mar 31, 2022 | -60,934.38% |
| Dec 31, 2021 | -731.92% |
| Sep 30, 2021 | -21,015.19% |
| Jun 30, 2021 | -18,148.91% |
| Mar 31, 2021 | -1,773.39% |